394 / 1631
2
2 x eBEACOPPesc
FDG-PET-2 positive:
End of therapy AND residual disease ≥ 2.5 cm AND positive PET: RT
4-6x
BEACOPPesc
4-6x
BEACOPPesc
2x
BEACOPPesc
FDG-PET-2 negative:
2 x eBEACOPPesc
Centrally reviewed PET/CT
Arm C
Arm D
Final analysis of the GHSG HD18 trial
GHSG HD18 trial
PET-guided therapy of advanced-stage HL